Compounds from Antrodia camphorata and use thereof

Abstract

The present invention relates to novel compounds from Antrodia camphorata and the use thereof.

1 . A compound having the formula  
       
         
           
           
               
               
           
         
       
       its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, 
 wherein  
 X is N or O;  
 R 1  is H, hydroxyl, C 1-10  alkyloxy, C 2-10  alkenyloxy, or C 2-10  alkynyloxy;  
 R 2  is H, hydroxyl, C 1-10  alkyl, C 2-10  alkenyl or C 2-10  alkynyl;  
 R 3  is C 1-10  alkyl, C 2-10  alkenyl or C 2-10  alkynyl;  
    denotes a single or double bond;  
 provided that  
 if X is 0, R 3  is absent;  
 if   denotes a single bond, the compound has the formula:  
                     
 
     
     
         2 . The compound of  claim 1 , wherein R 1  is C 2-6  alkenyloxy or C 2-6  alkynyloxy.  
     
     
         3 . The compound of  claim 2 , wherein C 2-6  alkenyloxy is substituted with C 1-6  alkyl.  
     
     
         4 . The compound of  claim 1 , wherein R 2  is isobutyl.  
     
     
         5 . A mixture from  Antrodia camphorata , which comprises the compounds of  claim 1 .  
     
     
         6 . The mixture of  claim 5 , which is prepared from water or organic solvent extract of mycelium of  Antrodia camphorate.    
     
     
         7 . The mixture of  claim 6 , wherein the organic solvent is ethanol.  
     
     
         8 . The mixture of  claim 5 , which inhibits factor increasing reactive oxygen species (ROS) generation.  
     
     
         9 . The mixture of  claim 5 , which inhibits TGF-β mediated inflammation and fibrosis.  
     
     
         10 . The mixture of  claim 9 , wherein the fibrosis is related to diabetic nephropathy, liver cirrhosis, idiopathic pulmonary fibrosis, rheumatoid arthritis, fibrosarcomas, arteriosclerosis, and scleroderma.  
     
     
         11 . The mixture of  claim 5 , which inhibits nitric oxide activities.  
     
     
         12 . The mixture of  claim 11 , which is for use in treating or preventing of epithelial cell carcinogenesis and free radical damages.  
     
     
         13 . The mixture of  claim 11 , which is for use in treating or preventing septic shock, ischemia, overexpression of cytokines, ulcer, ulcerative colitis, diabetes, arthritis, asthma, Alzheimer's disease, Parkinson's disease, multiple sclerosis, cirrhosis, allograft rejection, encephalomyelitis, meningitis, pancreatitis, peritonitis, vasculitis, lymphocytic choriomeningitis, glomerulonephritis, uveitis, ileitis, liver inflammation, renal inflammation, hemorrhagic shock, anaphylactic shock, burn, Crohn's disease or infection.  
     
     
         14 . A composition comprising a compound having the formula  
       
         
           
           
               
               
           
         
       
       its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, 
 wherein  
 X is N or O;  
 R 1  is H, hydroxyl, C 1-10  alkyloxy, C 2-10  alkenyloxy, or C 2-10  alkynyloxy;  
 R 2  is H, hydroxyl, C 1-10  alkyl, C 2-10  alkenyl or C 2-10  alkynyl;  
 R 3  is absent, H, hydroxyl or C 1-10  alkyl, C 2-10  alkenyl or C 2-10  alkynyl;  
    denotes a single or double bond;  
 provided that  
 if X is 0, R 3  is absent;  
 if   denotes a single bond, the compound has the formula:  
                     
 
     
     
         15 . The composition of  claim 14 , which inhibits factor increasing reactive oxygen species (ROS) generation.  
     
     
         16 . The composition of  claim 15 , which inhibits TGF-β mediated inflammation and fibrosis.  
     
     
         17 . The composition of  claim 16 , wherein the fibrosis is related to diabetic nephropathy, liver cirrhosis, idiopathic pulmonary fibrosis, rheumatoid arthritis, fibrosarcomas, arteriosclerosis, and scleroderma.  
     
     
         18 . The composition of  claim 14 , which inhibits nitric oxide activities.  
     
     
         19 . The composition of  claim 18 , which is for use in treating or preventing of epithelial cell carcinogenesis and free radical damages.  
     
     
         20 . The composition of  claim 18 , which is for use in treating or preventing septic shock, ischemia, overexpression of cytokines, ulcer, ulcerative colitis, diabetes, arthritis, asthma, Alzheimer's disease, Parkinson's disease, multiple sclerosis, cirrhosis, allograft rejection, encephalomyelitis, meningitis, pancreatitis, peritonitis, vasculitis, lymphocytic choriomeningitis, glomerulonephritis, uveitis, ileitis, liver inflammation, renal inflammation, hemorrhagic shock, anaphylactic shock, burn, Crohn's disease or infection.